Rankings
▼
Calendar
BBIO Q4 2025 Earnings — BridgeBio Pharma, Inc. Revenue & Financial Results | Market Cap Arena
BBIO
BridgeBio Pharma, Inc.
$14B
Q4 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$154M
+2521.2% YoY
Gross Profit
$139M
90.0% margin
Operating Income
-$185M
-120.1% margin
Net Income
-$197M
-127.9% margin
EPS (Diluted)
$-1.00
QoQ Revenue Growth
+27.7%
Cash Flow
Operating Cash Flow
-$56M
Free Cash Flow
-$61M
Stock-Based Comp.
$35M
Balance Sheet
Total Assets
$936M
Total Liabilities
$3.0B
Stockholders' Equity
-$2.1B
Cash & Equivalents
$570M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$154M
$6M
+2521.2%
Gross Profit
$139M
$4M
+3553.6%
Operating Income
-$185M
-$226M
+18.0%
Net Income
-$197M
-$265M
+25.6%
Revenue Segments
Product
$254M
67%
License and Service
$120M
31%
Royalty
$7M
2%
← FY 2025
All Quarters